off-the-shelf– tag –
-
CEA-Targeted CAR-NK Cells Derived from iPSCs Demonstrate Potent Anti-Tumor Activity Against Colorectal Cancer
Frontiers in Immunology Unknown Overview A new study reports that chimeric antigen receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs) exhibit potent anti-tumor activity against colorectal cancer. These CEA-target... -
China’s Xellsmart Secures FDA Fast Track for Off-the-Shelf Stem Cell Therapy XS411 in Parkinson’s Disease, Demonstrating Efficacy in Early-Stage Patients in Chinese Phase 1/2 Trial
Endpoints News China Overview China-based Xellsmart's off-the-shelf stem cell therapy, XS411, for Parkinson's disease, has received FDA Fast Track designation. XS411 aims to replace lost dopamine-producing neurons and restore neurologica... -
Century Therapeutics Targets Q4 2026 IND Submission for iPSC-Derived CNTY-813 in Type 1 Diabetes, Advances CAR-iT Cell Therapy CNTY-308 Towards Clinical Trials This Year
Century Therapeutics, Inc. (Press Release) USA Overview Century Therapeutics announced that it has completed its pre-IND meeting with the FDA for CNTY-813, an iPSC-derived cell therapy for Type 1 diabetes, targeting an Investigational Ne... -
Allogene Therapeutics’ Off-the-Shelf CAR-T Cema-cel Achieves 58.3% MRD Negativity in ALPHA3 Phase 2 LBCL Trial, Securing FDA RMAT and Fast Track Designations
Allogene Therapeutics, Inc. (Press Release) USA Overview Allogene Therapeutics announced strong Q2 2026 results, highlighting that its off-the-shelf CAR T-cell therapy, cema-cel, achieved a robust 58.3% minimal residual disease (MRD) neg... -
MD Anderson Researchers Identify Immature NK Cell Subpopulation in Donor Umbilical Cord Blood That Compromises CAR-NK Cell Therapy Antitumor Activity
Mirage News USA Overview Researchers at MD Anderson have discovered that a specific subpopulation of immature natural killer (NK) cells found in donor umbilical cord blood can diminish the antitumor activity of chimeric antigen receptor ... -
Fate Therapeutics Initiates Phase 2 Trial for iPSC-Derived Off-the-Shelf CAR T-Cell Therapy FT819 in Lupus Nephritis, Gains FDA IND Approval for Autoimmune FT839
Fate Therapeutics, Inc. (Press Release) USA Overview Fate Therapeutics reported significant advancements in its iPSC-derived off-the-shelf CAR T-cell immunotherapy pipeline, with the first patient dosed in the Phase 2 RECLAIM-LN study of... -
Allogeneic Cell Therapy Manufacturing: Broad Applicability, Scalability, and Automation Driving Future Advances
Industry Informational Article USA Overview This article provides a comprehensive overview of allogeneic cell therapy manufacturing, highlighting its advantages over autologous approaches, including broader applicability, superior scalab... -
Liv Hospital Highlights Off-the-Shelf Allogeneic CAR-T Manufacturing for Enhanced Accessibility via Standardized Donor Cells
Liv Hospital Turkey Overview Liv Hospital is championing the development of allogeneic CAR-T cell manufacturing as an 'off-the-shelf' solution, leveraging standardized donor cells to significantly improve treatment accessibility. This ad... -
Pioneering Off-the-Shelf Immunotherapy: CellFiber and Tidewave Bio Partner on Scalable 3D Cell Culture Manufacturing
BioSpace Japan Overview CellFiber and Tidewave Bio have launched a collaborative research program to evaluate CellFiber's proprietary 3D cell encapsulation technology for scalable immune cell manufacturing. This proof-of-concept study, l... -
Off-the-Shelf Advantage: How Scalable Manufacturing Drives Clinical Success for Combination Cell Therapies
Industry Publication USA Overview A recent industry analysis underscores the critical role of manufacturability and scalability from the earliest stages of development for the clinical success of cell therapies, particularly complex comb...
